aspirin has been researched along with Multiple Sclerosis in 24 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 9.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "Aspirin has the potential to ameliorate the disease process in multiple sclerosis (for example, by limiting some components of inflammation), but aspirin also has the potential to inhibit mitochondrial complex I activity, which is already reduced in multiple sclerosis." | 6.52 | Aspirin and multiple sclerosis. ( Emerson, MR; LeVine, SM; Lynch, SG; Tsau, S, 2015) |
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 5.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "In order to study the role of platelets in Multiple Sclerosis (MS) we assessed, in a group of patients during a quiescent phase of the disease, the plasma levels of beta-thromboglobulin (beta-TG) and platelet factor four (PF4) both in absence of treatment and during administration of aspirin (ASA) at the dose of 50 mg/daily." | 3.67 | Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis. ( Bortolon, F; Cananzi, AR; D'Andrea, G; Ferro-Milone, F; Grigoletto, F; Meneghini, F; Toldo, M, 1987) |
| "As part of a multicenter treatment trial of vascular dementia, this method was then used to analyze MR films in 13 patients with vascular dementia who all had an MR study at baseline and at 1 year." | 2.68 | Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis. ( Broderick, JP; Dhawan, AP; Gaskill, M; Khoury, J; Narayan, S, 1996) |
| "Aspirin has the potential to ameliorate the disease process in multiple sclerosis (for example, by limiting some components of inflammation), but aspirin also has the potential to inhibit mitochondrial complex I activity, which is already reduced in multiple sclerosis." | 2.52 | Aspirin and multiple sclerosis. ( Emerson, MR; LeVine, SM; Lynch, SG; Tsau, S, 2015) |
| "Colchicine treatment enhances PGE synthesis in control cells." | 1.27 | Lymphocyte adherence in multiple sclerosis: role of the cytoskeleton and prostaglandin E. ( Dore-Duffy, P; Zurier, RB, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (45.83) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 5 (20.83) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Vogelsang, A | 1 |
| Eichler, S | 1 |
| Huntemann, N | 1 |
| Masanneck, L | 1 |
| Böhnlein, H | 1 |
| Schüngel, L | 1 |
| Willison, A | 1 |
| Loser, K | 1 |
| Nieswandt, B | 1 |
| Kehrel, BE | 1 |
| Zarbock, A | 1 |
| Göbel, K | 1 |
| Meuth, SG | 1 |
| Kever, A | 1 |
| Nelson, KE | 1 |
| Aguerre, IM | 1 |
| Riley, CS | 1 |
| Boehme, A | 1 |
| Lee, NW | 1 |
| Strauss Farber, R | 1 |
| Levin, SN | 1 |
| Stein, J | 1 |
| Leavitt, VM | 1 |
| Modi, KK | 1 |
| Sendtner, M | 1 |
| Pahan, K | 1 |
| Tsau, S | 1 |
| Emerson, MR | 1 |
| Lynch, SG | 1 |
| LeVine, SM | 1 |
| Eckermann, S | 1 |
| Coory, M | 1 |
| Willan, AR | 1 |
| Cohen, M | 1 |
| Rocher, F | 1 |
| Brunschwig, C | 1 |
| Lebrun, C | 1 |
| Graham, DF | 1 |
| Hadlow, N | 1 |
| Tsokos, N | 1 |
| Oates, R | 1 |
| Shaygannejad, V | 1 |
| Janghorbani, M | 1 |
| Ashtari, F | 1 |
| Zakeri, H | 1 |
| Frohman, L | 1 |
| Turbin, R | 1 |
| Bielory, L | 1 |
| Wolansky, L | 1 |
| Lambert, WC | 1 |
| Cook, S | 1 |
| MILLER, H | 1 |
| NEWELL, DJ | 2 |
| RIDLEY, A | 1 |
| MILLER, HG | 1 |
| FOSTER, JB | 1 |
| BARWICK, DD | 1 |
| BREWIS, RA | 1 |
| BOYLE, RW | 1 |
| TABET, RC | 1 |
| WIGHTMAN, BK | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 1 |
| Wingerchuk, DM | 1 |
| Benarroch, EE | 1 |
| O'Brien, PC | 1 |
| Keegan, BM | 1 |
| Lucchinetti, CF | 1 |
| Noseworthy, JH | 1 |
| Weinshenker, BG | 1 |
| Rodriguez, M | 1 |
| Offner, H | 1 |
| Danneskiold-Samsøe, B | 1 |
| Dore-Duffy, P | 6 |
| Zurier, RB | 4 |
| Broderick, JP | 1 |
| Narayan, S | 1 |
| Gaskill, M | 1 |
| Dhawan, AP | 1 |
| Khoury, J | 1 |
| Donovan, C | 1 |
| Cananzi, AR | 1 |
| Ferro-Milone, F | 1 |
| Grigoletto, F | 1 |
| Toldo, M | 1 |
| Meneghini, F | 1 |
| Bortolon, F | 1 |
| D'Andrea, G | 1 |
| Steinberg, AD | 1 |
| Marcus, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aspirin for Exercise in Multiple Sclerosis (ASPIRE): A Double-Blind RCT of Aspirin or Acetaminophen Pretreatment to Improve Exercise Performance in Multiple Sclerosis (MS)[NCT03824938] | Phase 3 | 60 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in body temperature from pre- to post- maximal exercise test. (NCT03824938)
Timeframe: from start of exercise test until self-reported exhaustion, up to 30 minutes
| Intervention | degrees Fahrenheit (Mean) |
|---|---|
| Placebo | 0.68 |
| Aspirin | 0.006 |
| Acetaminophen | 0.31 |
Duration of time exercising before reaching peak exertion, defined as cadence drop below 40 revolutions per minute (RPM) for >/= 5 seconds, or patient reaches volitional exhaustion in accordance with American Thoracic Society standard test termination criteria. (NCT03824938)
Timeframe: from start of exercise test until self-reported exhaustion, up to 30 minutes
| Intervention | seconds (Mean) |
|---|---|
| Placebo | 551.7 |
| Aspirin | 331.6 |
| Acetaminophen | 578.2 |
3 reviews available for aspirin and Multiple Sclerosis
| Article | Year |
|---|---|
Aspirin and multiple sclerosis.
Topics: Animals; Aspirin; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Sclerosis; Platelet | 2015 |
An approach to the use of immunosuppressive drugs in nonmalignant diseases.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Chlorambucil; Cyclophosphamide; G | 1973 |
Platelet function.
Topics: Adenine Nucleotides; Afibrinogenemia; Age Factors; Anemia, Hypochromic; Animals; Aspirin; Blood Cell | 1969 |
4 trials available for aspirin and Multiple Sclerosis
| Article | Year |
|---|---|
ASPIRE trial: study protocol for a double-blind randomised controlled trial of aspirin for overheating during exercise in multiple sclerosis.
Topics: Adult; Aspirin; Child, Preschool; Double-Blind Method; Exercise; Female; Humans; Infant; Male; Multi | 2020 |
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.
Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross | 2012 |
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
Topics: Administration, Oral; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross-Ov | 2005 |
Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis.
Topics: Aspirin; Brain; Brain Ischemia; Dementia, Vascular; Double-Blind Method; Female; Humans; Magnetic Re | 1996 |
17 other studies available for aspirin and Multiple Sclerosis
| Article | Year |
|---|---|
Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple Sclerosis.
Topics: Animals; Aspirin; Blood Platelets; Brain; CD4-Positive T-Lymphocytes; Disease Models, Animal; Dose-R | 2021 |
Up-regulation of ciliary neurotrophic factor in astrocytes by aspirin: implications for remyelination in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Astrocytes; Cells, Cultured; C | 2013 |
Indirect comparison: relative risk fallacies and odds solution.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Aspirin; Atrial Fibrillat | 2009 |
Recurrent pericarditis due to natalizumab treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Chest Pain; Colchicine; D | 2009 |
A case of hypertension with virilisation during pregnancy.
Topics: Adult; Aspirin; Brenner Tumor; Calcium; Cesarean Section; Dehydroepiandrosterone Sulfate; Dietary Su | 2010 |
Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child.
Topics: Antibodies, Anticardiolipin; Aspirin; Autoimmune Diseases of the Nervous System; Biopsy; Child; Diag | 2003 |
Multiple sclerosis. Trials of maintenance treatment with prednisolone and soluble aspirin.
Topics: Aspirin; Humans; Multiple Sclerosis; Prednisolone | 1961 |
MULTIPLE SCLEROSIS: THERAPEUTIC TRIALS OF CHLOROQUINE, SOLUBLE ASPIRIN, AND GAMMAGLOBULIN.
Topics: Aspirin; Chloroquine; gamma-Globulins; Humans; Multiple Sclerosis | 1963 |
ANALGESIC EFFECT OF PRODILIDINE HYDROCHLORIDE (5054) IN ELDERLY PATIENTS WITH CHRONIC PAIN SYNDROME.
Topics: Analgesics; Analgesics, Non-Narcotic; Antipyretics; Arthritis; Arthritis, Rheumatoid; Aspirin; Chron | 1964 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
Effect of prostaglandins and aspirin on active E-rosette formation in patients with multiple sclerosis.
Topics: Adult; Aged; Alprostadil; Arthritis, Rheumatoid; Aspirin; Central Nervous System Diseases; Cyclic AM | 1982 |
E-rosette formation in multiple sclerosis.
Topics: Aspirin; Humans; Leukocyte Adherence Inhibition Test; Leukocytes; Multiple Sclerosis; Prostaglandins | 1980 |
E-rosette formation in normals and patients with multiple sclerosis: effect of prostaglandin and aspirin.
Topics: Adult; Animals; Aspirin; Cell Adhesion; Female; Humans; Lymphocytes; Male; Measles; Middle Aged; Mul | 1979 |
Lymphocyte adherence in multiple sclerosis: effect of aspirin.
Topics: Aspirin; Cell Adhesion; Cells, Cultured; Female; Humans; In Vitro Techniques; Lymphocytes; Male; Mea | 1979 |
Functional desensitization of monocytes from patients with multiple sclerosis due to prostaglandin E.
Topics: Aspirin; Cells, Cultured; Cyclic AMP; Cytotoxicity, Immunologic; Humans; Monocytes; Multiple Scleros | 1991 |
Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis.
Topics: Adult; Aspirin; beta-Thromboglobulin; Female; Humans; Male; Multiple Sclerosis; Platelet Aggregation | 1987 |
Lymphocyte adherence in multiple sclerosis: role of the cytoskeleton and prostaglandin E.
Topics: Aspirin; Benzimidazoles; Cell Adhesion; Colchicine; Cytoskeleton; Dinoprostone; Humans; Lymphocytes; | 1986 |